Notably, anthracyclines, ICIs, tyrosine kinase inhibitors, and hormonal therapies can accelerate CKM progression by inducing cardiotoxicity, nephrotoxicity, and metabolic diseases. This evidence concerns the gene CKM and Other metabolic disease.